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Background. The present study aims to examine the oxidative stress-related activation of poly(ADP-ribose) polymerase (PARP),
a cause of parthanatos in circulating mononuclear leukocytes of patients with chronic heart failure (CHF), that was rarely
investigated in the human setting yet. Methods. Patients with CHF (n = 20) and age- and body mass index-matched
volunteers (n = 15) with a normal heart function were enrolled. C-reactive protein, N-terminal probrain-type natriuretic peptide
(pro-BNP), plasma total peroxide level (PRX), plasma total antioxidant capacity (TAC), oxidative stress index (OSI), leukocyte
lipid peroxidation (4-hydroxynonenal; HNE), protein tyrosine nitration (NT), poly(ADP-ribosyl)ation (PARylation), and
apoptosis-inducing factor (AIF) translocation were measured in blood samples of fasting subjects. Results. Plasma PRX,
leukocyte HNE, NT, PARylation, and AIF translocation were significantly higher in the heart failure group. Pro-BNP levels in
all study subjects showed a significant positive correlation to PRX, OSI, leukocyte HNE, NT, PARylation, and AIF translocation.
Ejection fraction negatively correlated with the same parameters. Among HF patients, a positive correlation of pro-BNP with
PRX, OSI, and PARylation was still present. Conclusions. Markers of oxidative-nitrative stress, PARP activation, and AIF
translocation in blood components showed correlation to reduced cardiac function and the clinical appearance of CHF. These
results may reinforce the consideration of PARP inhibition as a potential therapeutic target in CHF.
1. Introduction
Heart failure as the outcome of a variety of cardiovascular
diseases implies increasing burden for global healthcare
systems [1]. Various pathophysiological conditions including
ischemic heart disease, cardiomyopathies, myocarditis, long-
standing arrhythmias, metabolic, hematologic, and genetic
disorders may lead to impaired myocardial function [2, 3].
The progression of cardiovascular dysfunction to heart
failure is a complex phenomenon and involves the activation
of numerous secondary pathways.
Experimental and clinical studies provided a wide range
of evidence of increased oxidative-nitrative stress in heart
failure [2]. The integrity of cardiac myocytes is deteriorated
by reactive species-damaging proteins, DNA, and membrane
lipids. The increased oxidative-nitrative stress leads to the
activation of various enzymes including matrix metallo-
proteinases and poly(ADP-ribose) polymerase-1 (PARP).
Poly(ADP-ribose) polymerase-1 (PARP) is the major
isoform of an enzyme family, with multiple regulatory func-
tions. Upon activation, mainly by DNA single-strand breaks,
it cleaves NAD+ into nicotinamide and ADP-ribose, forms
long branches of ADP-ribose polymers, and binds them
to several nuclear target proteins (PARylation) [4]. PARP
activation exerts its physiological and pathological effects
via two principal mechanisms [5]. On one hand, (i) it
PARylates acceptor proteins including histones, transcrip-
tion factors, and the PARP itself. PARylation contributes to
DNA repair and to the regulation of gene expression. The
protein expression of various proinflammatory mediators
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 1249614, 12 pages
https://doi.org/10.1155/2017/1249614
(cytokines, chemokines, iNOS, and ICAM-1) is regulated
by PARP at the transcriptional level. On the other hand,
(ii) oxidative-nitrative stress-induced overactivation of PARP
consumes NAD+ and consequently ATP, culminating in cell
dysfunction and necrotic cell death [3].
Poly(ADP-ribosyl)ation was activated under critical situ-
ations with oxidative-nitrative stress-induced DNA damage
and was shown to play a regulatory role in different cell death
pathways, such as apoptosis, autophagy, necroptosis, and
parthanatos [6].
During caspase-dependent apoptosis, PARP-1 is cleaved
by caspases preventing further loss of NAD+ and providing
energy for the apoptotic processes [7]. PAR accumulation
can induce a form of caspase-independent death trigger-
ing the translocation of mitochondrial factors, including
apoptosis-inducing factor (AIF). Pathogenic PAR polymer
translocates to the mitochondria from the nucleus to mediate
AIF release. AIF translocation to the nucleus promotes chro-
matin condensation and DNA degradation. This crosstalk
between nucleus and mitochondria is the key point in special
cell death pathway called parthanatos [8].
The present study aims (1) to examine parthanatos
phenomenon (oxidative-nitrative stress, PARP activation,
and AIF translocation) in blood components of patients with
chronic heart failure, (2) to assess the possible correlation
with the severity of the disease, and (3) to identify clinical
parameters that may play a role in the development of
parthanatos of circulating mononuclear cells in chronic
heart failure.
2. Materials and Methods
2.1. Participants. 20 patients between the age of 50 and
70 years with known chronic heart failure (CHF) having
clinically stable cardiopulmonary state (NYHA II-III) were
enrolled at the Heart and Vascular Center of Semmelweis
University, Budapest, Hungary. Heart failure was diagnosed
according to the actual guideline of the European Society of
Cardiology (ESC) published in 2016. In accordance with
the ESC guideline recommendations, transthoracic echocar-
diography was used to evaluate cardiac structure and func-
tion and to measure left ventricular ejection fraction (EF)
according to the modified Simpson’s rule (apical biplane
method with tracing of endocardial borders). CHF diagnosis
was verified by the reduced systolic function defined as
ejection fraction (EF) below 40%. NYHA stages were also
determined according to the ESC guideline. The etiology of
the heart failure was divided to ischemic (having known
ischemic heart disease (IHD), N = 9) or nonischemic
(N = 11) origin, without further evaluation [9]. Transtho-
racic echocardiography performed within the last 3 months
before enrollment was accepted if no significant change of
patient condition was observed. In case of new symptoms,
or lacking echocardiography in the previous 3 months,
cardiac ultrasound was repeated. Volunteers matched by
age, BMI, and cardiovascular risk factors (smoking, diabetes
mellitus, hypertension, and IHD) with normal systolic
function served as controls (n = 15). Exclusion criteria were
insulin-treated diabetes mellitus, acute coronary syndrome,
stroke or major surgical intervention in the past 3 months,
acute or chronic inflammatory diseases, and neoplasm.
All procedures complied with the Helsinki Declaration of
the World Medical Association and were approved by the
institutional and regional ethics committee of Semmelweis
University (7268-0/2011-EKU). Written informed consent
was acquired from all participants.
2.2. Clinical Examinations. After enrollment, all partici-
pants completed an interviewer-assisted questionnaire that
included demographic (age, gender, and lifestyle) and general
medical (medication, known illnesses, and family history)
inquiries. Current smoking was defined as one or more
cigarette/day on a weekly average. Height and weight were
measured on a calibrated stadiometer in light clothing. BMI
was calculated as weight (kg)/height (m2). Transthoracic
two-dimensional echocardiography was performed to detect
left ventricular end diastolic diameter (LVEDD), left ven-
tricular end systolic diameter (LVESD), and ejection frac-
tion. Fasting blood samples were collected from all subjects
for C-reactive protein (CRP), N-terminal probrain-type
natriuretic peptide (pro-BNP), oxidative-nitrative stress,
PARP activity, and AIF translocation measurements. CRP
and pro-BNP levels were determined by immunochemical
methods (Cobas Integra 400 Plus and Cobas E411 analyzers,
resp.; Roche, Basel, Switzerland) at the Central Laboratory of
the Heart and Vascular Center of Semmelweis University.
Ejection fraction, LVEDD, LVESD, and plasma pro-BNP
levels of individuals were used to characterize cardiac func-
tion. Brain natriuretic peptide (BNP) is a member of a family
of human natriuretic peptides. Before its activation, BNP is
stored as the precursor, pro-BNP. After pro-BNP is secreted
in response to volume overload resulting to myocardial
stretch, it is cleaved to the biologically inactive N-terminal
fragment and the biologically active hormone BNP. The
2 fragments are secreted into the plasma in equimolar
mounts, and both have been clinically evaluated for use
in the management of congestive heart failure. The secreted
N-terminal fragment is usually referred to as simplified
plasma pro-BNP. According to the newest guideline for the
diagnosis and treatment of the heart failure of the European
Society of Cardiology, elevated natriuretic peptides help to
establish initial diagnosis, identifying those who require
further cardiac investigation and patients with values below
the threshold (125pg/mL) for the exclusion of heart failure.
Natriuretic peptides are strong predictors of mortality in
chronic heart failure, and pro-BNP-guided therapies are
shown to improve the outcome in heart failure [10–13].
2.3. Oxidative-Nitrative Stress and PARP Activation. Plasma
total peroxide level (PRX) was measured by Oxystat kit
(Biomedica, Vienna, Austria) according to the user’s manual.
Absorption was detected at 450nm by BioTek Powerwave
XS Spectrophotometer (BioTek, BioTek Instruments, Inc.,
Winooski, VT, USA). PRX measurements are available from
11 controls and 12 CHF patients. Total plasma antioxidant
capacity (TAC) was measured by OxiSelect™ TAC Assay
Kit (Cell Biolabs, San Diego) according to the user’s manual.
Absorption was detected at 490 nm by BioTek Powerwave XS
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Spectrophotometer. Results are given in CRE (μmol copper
reducing equivalent). TAC measurements are available from
15 controls and 19 CHF patients. Oxidative stress index
(OSI) is given as the ratio of total peroxide and TAC. For
the determination of cellular lipid peroxidation, protein
tyrosine nitration, PARP activation, and AIF translocation,
circulating mononuclear leukocytes, were isolated by gra-
dient centrifugation (Histopaque-1077, Sigma-Aldrich, St.
Louis, MO, USA). Cellular lipid peroxidation, protein
tyrosine nitration, and PARP activation were estimated
by immunohistochemical staining of methanol-fixed leuko-
cyte smears with rabbit polyclonal anti-4-hydroxynonenal
(HNE) (Abcam, Cambridge, UK; 1 : 200, overnight, 4°C), rab-
bit polyclonal antinitrotyrosine (NT) (Millipore, Temecula,
CA, USA; 1 : 80, overnight, 4°C), mouse monoclonal anti-
PAR (Tulip, West Point, PA, USA; 1 : 500, overnight, 4°C),
and anti-AIF rabbit polyclonal (Millipore; 1 : 100, 4°C,
overnight) antibodies. Measurements of AIF translocation
are available in 11 patients with CHF and 13 control subjects.
Secondary labeling was achieved by biotinylated mouse
and rabbit immunoglobulin-specific antibodies (Vector Lab-
oratories, Burlingame, CA, USA). Avidin-horseradish perox-
idase complex and brown-colored diaminobenzidine (DAB)
(HNE) or black-colored nickel-enhanced DAB (NT, PAR,
and AIF) (Vector) were used to visualize specific labeling.
Blue-colored hematoxyilin (HNE) or red-colored Nuclear
Fast Red (NFR) (NT, PAR, and AIF) (Sigma, MO, USA)
was used as counterstain. Microscopic images of immuno-
labelled smears were acquired by Zeiss Imager A1 light
microscope using 20x/0.45 and 40x/0.75 objectives, Axio-
Cam MRc5 camera, and AxioVision Rel. 4.8 software
(Carl Zeiss Microscopy GmbH, Jena, Germany). The ratio
of the positive cellular area and total cellular area (HNE
area (%) and NT area (%)) or the ratio of positive nuclear
area and total nuclear area (PAR area (%) and AIF area
(%)) analyzing at least 300 cells per smear was calculated by
computer-based evaluation (MBF ImageJ, NIH, Bethesda,
MA, USA).
2.4. Statistical Analysis. Sample size calculation was per-
formed prior to the recruitment of study subjects based on
two measured parameters: PRX and PAR areas. Standard
deviation (SD) of these parameters were estimated using
the data of our previous measurement among the healthy
human subjects (n = 25) (unpublished data). The mean of
PRX area was 313.4μmol/l with an SD of 118.5μmol/l, while
the mean of PAR area was 12.45% with an SD of 8.72%.
Calculating 80% power for p < 0 05, the sample size of 15
was found to be eligible to detect 125.94μmol/l and 9.3%
change in PRX and PAR areas, respectively, which was
decided to be sufficient to detect the expected change of
120μmol/l and 10% in CHF patients [14].
Results are expressed as mean± SD for normally dis-
tributed variables and median (interquartile range) for
nonnormally distributed variables. Variables that violated
the normality assumption (CRP, pro-BNP, HNE area, NT
area, PAR area, and AIF area) were log-transformed before
using them in the statistical models. Participants’ charac-
teristics by study group were compared using two-tailed
independent samples t-test. The distribution of categorical
variables (gender, smoking, presence of diabetes mellitus,
hypertension, or IHD) in the different groups was compared
by chi-square test. The possible relationship between clinical
parameters and oxidative-nitrative stress, PARP activation,
AIF translocation in the study cohort, and among CHF
patients was examined by Pearson’s correlation test and
linear regression models. In case of multiple significant cor-
relations in the CHF group, multivariate linear regression
models were implemented. Missing values were treated as
missing. In all cases, p < 0 05 was considered significant
(SPSS 22.0 and Graphpad Prism and StatMate softwares).
3. Results
3.1. Clinical Parameters and Anamnestic Data. In our study,
20 patients with chronic heart failure (CHF) and 15 controls
were enrolled. The gender composition of the two groups was
similar. Both age and body mass index of the two study
groups were also comparable. There was no significant dif-
ference concerning the prevalence of hypertension, diabe-
tes mellitus, ischemic heart disease, and smoking habit.
The level of the inflammatory marker CRP was not signif-
icantly different in the study cohorts. Ejection fraction was
significantly lower; LVEDD and LVESD were significantly
higher in the diseased group. The level of pro-BNP was
markedly increased in CHF patients. The median pro-
BNP of control group is slightly elevated according to
exclusionary cut-off point mentioned in the actual guide-
line of the European Society of Cardiology (125 pg/mL);
however, these subjects showed no clinical signs of cardiac
failure so the elevation of pro-BNP is most probably due
to other conditions [9] (Table 1). In our CHF group,
patients having IHD do not differ in any abovementioned
parameters from their non-IHD mates except from signifi-
cantly reduced LVEDD (CHF without IHD: 68.6± 10.6mm
versus CHF with IHD: 54.2± 3.5mm, p < 0 05) and LVESD
(CHF without IHD: 59.5± 9.9mm versus CHF with IHD:
45.4± 3.8mm, p < 0 05).
3.2. Oxidative, Nitrative Stress, PARP Activation, and AIF
Translocation in Blood Components. Plasma PRX level was
significantly increased in the CHF group indicating that these
patients had more intensive oxidative stress compared to
controls. On the other hand, TAC was not significantly
elevated in CHF patients (p = 0 066). After calculating OSI,
we also found a nonsignificant elevation of this parameter
among CHF patients (p = 0 059). Similarly to PRX, cellular
oxidative stress assessed by leukocyte HNE immunostaining
intensity was also significantly increased in the CHF group
compared to controls. We observed significant (p < 0 05)
elevation in leukocyte NT staining intensity too, which may
suggest an elevated nitrosative environment in CHF. The
degree of PAR labeling in circulating mononuclear cells,
reflecting the PARP activity in these cells, was significantly
elevated in the disease group. Furthermore, in the CHF
group, the number of AIF-positive cells was significantly
increased compared to the control group (Figures 1 and 2).
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3.3. Correlation of Oxidative Stress and Signs of Parthanatos
with the Indicators of Cardiac Function. Examining the
correlation between oxidative-nitrative stress, PARP activa-
tion, AIF translocation, and the used indicators of cardiac
function, such as ejection fraction and pro-BNP levels in all
study subjects, revealed a significant positive correlation of
the latter with all the following parameters: PRX level, OSI,
leukocyte HNE, tyrosine nitration, PARylation, and AIF
translocation. EF negatively correlated with same parame-
ters: PRX, OSI, leukocyte HNE, tyrosine nitration, PARP
activation, and AIF translocation. The observed relationships
may imply a negative correlation between cardiac function,
oxidative-nitrative stress, PARP activation, and AIF translo-
cation (Table 2, Figures 3(a), 3(c), 3(e), 3(g), 3(i), and 3(k)).
Furthermore, AIF translocation also (log[AIF cell %])
positively correlated with LVEDD (R = 0 497, p < 0 05).
Further, analyzing the same relationships in the CHF
group only showed that plasma PRX level, OSI, and PARP
activity in circulating leukocytes positively correlate with
pro-BNP levels of the chronic heart failure patients. These
results suggest a positive correlation of oxidative stress and
PARP activation, with the actual clinical appearance of
cardiac decompensation reflecting the severity of the chronic
heart failure. On the other hand, similar correlation was not
observed in case of HNE, tyrosine nitration, or AIF transloca-
tion (Table 2, Figures 3(b), 3(d), 3(f), 3(h), 3(j), and 3(l)). In
the control group, however, there was no correlation between
oxidative stress and the signs of parthanatos and the indica-
tors of cardiac function in the control group (data not shown).
Still, in the CHF group, both LVEDD and LVESD
negatively correlated with plasma PRX level and OSI
(R = −0 819, p < 0 01; R = −0 838, p < 0 01 and R = − 0793,
p < 0 05; R = −0 817, p < 0 01, resp.) where both LVEDD
and LVESD negatively correlated to the presence of
ischemic heart disease (R = −0 660, p < 0 05 and R = −0 673,
p < 0 05, resp.).
3.4. Correlation of Oxidative Stress and Signs of Parthanatos
with Anamnestic Data and Clinical Parameters. In the whole
study cohort, plasma PRX level and OSI positively corre-
lated with the presence of ischemic heart disease (R = 0 587,
p < 0 01 and R = 0 573, p < 0 01, resp.) and smoking habit
(R = 0 552, p < 0 01 and R = 0 525, p < 0 01, resp.). Leukocyte
nitrative stress (log[NT area (%)]) positively correlated with
type 2 diabetes mellitus (R = 0 376, p < 0 05).
In the CHF group, total plasma peroxide level and OSI
positively correlated with the presence of ischemic heart
disease (R = 0 676, p < 0 05 and R = 0 687, p < 0 05).
3.5. Determinants of Oxidative Stress in Chronic Heart
Failure. According to our results, plasma PRX levels and
OSI in the CHF patients positively correlated both with the
pro-BNP levels and the occurrence of ischemic heart disease
and negatively with the LVESD and LVEDD diameters. In
order to estimate the role of these variables in the develop-
ment of oxidative stress, multivariate regression was imple-
mented. The analysis showed that serum pro-BNP and IHD
are independent determinants of plasma total peroxide level,
and together they can explain the 97.7% of its variability. On
the other hand, only serum pro-BNP was found to be the
independent determinant of OSI (Table 3).
4. Discussion
According to the results of both experimental and clinical
studies, increased oxidative stress is characteristic for heart
failure [3, 4, 15]. In some animal models, a positive correla-
tion between myocardial level of reactive oxygen species
(ROS) and ventricular dysfunction was observed [3]. Lipid
peroxidation was also shown to be elevated in patients with
hypertrophic cardiomyopathy, and the level of oxidative
stress was correlated to left ventricular dilation and systolic
dysfunction [15]. Our results describing the increased plasma
and mononuclear leukocyte lipid peroxidation among
patients with CHF and the found correlation of plasma
PRX with cardiac performance and pro-BNP levels corre-
spond to and expend these previous findings. Although
several experimental data provided evidence for the role
of ROS in progression of heart failure, the results of
clinical trials examining the possible beneficial effect of
antioxidants—as vitamin C, vitamin A, and co-enzyme
Q—are controversial. Attenuation of symptoms was reported
in some cases; however, in other studies neither the symp-
toms nor the exercise capacity was improved. On the other
hand, it is also worth to point the fact that some drugs already
used effectively in the clinical management of heart failure
Table 1: Clinical parameters and anamnestic data of study groups.
Control
Chronic heart
failure
Sign
Number 15 20
Gender: male/female 13/2 16/4 n.s.
Age (years) 63.3± 9.4 68.9± 8.0 n.s.
Body mass index
(kg/m2)
28.9± 3.3 27.9± 4.9 n.s.
EF (%) 60.0± 5.3 24.9± 5.9 p < 0 01
LVEDD (mm) 48.2± 4.6 63.0± 11.1 p < 0 01
LVESD (mm) 31.4± 5.1 54.0± 10.6 p < 0 01
Pro-BNP (pg/mL)
148.4
(47.9; 178.0)
2338.5
(1475.6; 4597.5)
p < 0 01
CRP (mg/L) 5.0 (1.3; 6.1) 2.6 (1.5; 4.9) n.s.
Smoking (N) 1 3 n.s.
Diabetes mellitus (N) 2 4 n.s.
Hypertension (N) 13 19 n.s.
Ischemic heart
disease (N)
3 9 n.s.
Statistical analysis: continuous variables are presented as mean ± SD or
median (IQR) in case of variables that violated the normal distribution;
categorical variables are presented as the number of affected patients in
each group. In order to test the possible differences between the study
groups, t-test or chi-square test was performed. Sign: significance;
N: number; n.s.: nonsignificant; EF: ejection fraction; LVEDD: left
ventricular end diastolic diameter; LVESD: left ventricular end systolic
diameter; Pro-BNP: N-terminal probrain-type natriuretic peptide;
CRP: C-reactive protein.
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Figure 1: Parthanatos in blood components. (a) Plasma total peroxide level. Data are presented as mean± SEM. (b) Total antioxidant
capacity (TAC) change in TAC values in the CHF and control group. Data are presented as mean± SEM. (c) Oxidative stress index (OSI)
is given as the ratio of total peroxide and TAC. Data are presented as mean± SEM. (d) Oxidative stress in circulating leukocytes. The
percentage of positively labeled cellular area compared to total cellular area was calculated on anti-4-hydroynonenal- (HNE-)
immunostained leukocyte smears. Data are presented as median (IQR). (e) Nitrative stress in circulating leukocytes. The percentage of
positively labeled cellular area compared to the total cellular area was calculated on antinitrotyrosine- (NT-) immunostained leukocyte
smears. Data are presented as median (IQR). (f) PARP activity in mononuclear cells. Immunohistochemical labeling of poly(ADP-ribose)
(PAR). The end product of PARP was evaluated as described above. Data are presented as median (IQR). (g) AIF translocation in
mononuclear cells. Immunohistochemical labeling of AIF. The percentage of positively labeled nuclei compared to the total number of
nuclei was calculated. Data are presented as median (IQR) ∗p < 0 05.
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Figure 2: Representative microscopic image of anti-4-hydoxynonenal (HNE), antinitrotyrosine (NT), anti-poly(ADP-ribose) (PAR) stained
leukocyte smears, and AIF translocation. The brown-colored (HNE) or black-colored (NT, PAR, and AIF) diamino-benzidine (DAB)
represents specific labeling; the blue-colored hematoxylin (HNE) or red-colored Nuclear Fast Red (NFR) (NT, PAR, and AIF) was used
for counterstaining. The microscopic images were taken by light microscopy using 40x/0.75 objective; the length of the scale bar is 50μm.
The ratio of positively stained nuclear area is increased in CHF patients’ leukocyte smears stained against PAR and AIF.
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may have antioxidant properties, which may play a role in
their therapeutic efficacy [4].
In our study cohort, plasma PRX level was also positively
correlated to the occurrence of ischemic heart disease (IHD).
The positive correlation with IHD could be observed both in
the whole study cohort and in the isolated CHF group. The
effect of acute ischemic episode of the heart on oxidative
stress was previously examined in patients after acute
myocardial infarction with or without cardiogenic shock,
and increased oxidative stress was demonstrated in both
cases [14, 16]. According to our results, long-term, chronic
ischemic environment may also induce further aggravation
of plasma PRX levels in CHF patients. On the other hand,
this change is also accompanied by increased plasma TAC,
resulting to a not significant elevation of OSI.
In our total study cohort, LVEDD and LVESD showed no
correlation with PRX; however, in the isolated CHF groups,
cardiac dimensions negatively correlated with both total
plasma peroxide levels and the presence of ischemic heart
disease. The background of the negative correlation found
between cardiac dimensions and total peroxide level is not
yet clarified. Our observations that IHD among CHF patients
is accompanied by elevated plasma PRX, but less increased
cardiac diameters, may explain this phenomenon. On the
other hand, it is possible that ROS production is exhausted
in the progress of excess cardiac remodeling.
Several previous studies demonstrated the elevation of
nitrative stress in various forms of acute and chronic heart
failure both in experimental models and human biopsies
[17]. Protein nitration is one of the characteristic reactions
of the potent oxidant peroxynitrite formed in the spontane-
ous reaction of superoxide and nitric oxide. Increased nitra-
tion of sacro/endoplasmic reticulum Ca++ ATPase (SERCA)
was reported in human hearts of dilated cardiomyopathy.
SERCA inactivation by nitration may lead to the reduced
function of the ion pump, hence compromising lusitropy as
an early event in the development of CHF [18]. Furthermore,
overexpression of inducible NO synthase (iNOS) was dem-
onstrated in human hearts with depressed contractility.
iNOS-positive patients had larger left ventricular volume
and depressed function; however, the preserved NO genera-
tion was associated with higher cardiac work [19]. In our
study, significant elevation of protein nitration in circulating
leukocytes was observed in the heart failure group. Addi-
tional pathophysiological alterations may have relevant
impact on the creation of nitrative stress. According to our
observation, protein nitration correlates with the presence
of diabetes mellitus, which corresponds to the previous
Table 2: Pearson correlation of oxidative-nitrative stress markers, PARP activity, AIF translocation with ejection fraction, and
pro-BNP levels.
All subjects CHF patients
EF (%) Log[pro-BNP (pg/mL)] EF (%) Log[pro-BNP (pg/mL)]
Total peroxide (μmol/L)
R −0.458 0.531 −0.245 0.577
p 0.028 0.009 0.444 0.049
N 23 23 12 12
TAC (μmol CRE)
R −0.244 0.142 0.226 −0.412
p 0.165 0.424 0.351 0.08
N 34 34 19 19
OSI (total peroxide/CRE)
R −0.466 0.537 −0.339 0.630
p 0.025 0.008 0.291 0.028
N 23 23 12 12
Log[HNE area (%)]
R −0.682 0.628 0.336 0.331
p 0.00002 0.0001 0.187 0.195
N 32 32 17 17
Log[NT area (%)]
R −0.368 0.497 −0.213 0.051
p 0.032 0.009 0.381 .836
N 34 34 19 19
Log[PAR area (%)]
R −0.466 0.576 −0.004 0.474
p 0.006 0.000 0.986 0.047
N 33 33 18 18
Log[AIF cell (%)]
R −.431 .472 0.000 −.169
p 0.035 0.020 0.999 0.620
N 24 24 11 11
Statistical analysis: Pearson correlation was performed between continuous variables. In order to provide the normal distribution of variables that
initially violated normality, logarithmic transformation was implemented. R: Pearson coefficient; p: significance; N: number of cases in each calculation.
pro-BNP: N-terminal probrain-type natriuretic peptide; TAC: total antioxidant capacity; CRE: copper reducing equivalent; OSI: oxidative stress index;
HNE: anti-4-hydroxynoneal; NT: nitrotyrosine; PAR: poly(ADP-ribose); AIF: apoptosis-inducing factor.
7Oxidative Medicine and Cellular Longevity
2 3 4
‒500
0
500
1000
1500
2000
R
(272.16 ± 94.73)x ‒ (232.2 ± 279.6)
p
Log[pro-BNP (pg/mL)]
To
ta
l p
er
ox
id
e (
휇
m
ol
/L
)
2 = 0.282
= 0.009
(a)
2 3 4
‒500
0
500
1000
1500
2000
2 = 0.333
p
To
ta
l p
er
ox
id
e (
휇
m
ol
/L
)
Log[pro-BNP (pg/mL)]
(949.4 ± 424.9)x ‒ (2662.4 ± 1514.2)
R
= 0.049
(b)
2 3 4
‒1.0
‒0.5
0.0
0.5
1.0
1.5
2.0
2.5
2 = 0.29
p
O
SI
 (t
ot
al
 p
er
ox
id
e/
TA
C)
Log[pro-BNP (pg/mL)]
= 0.008
R
(0.38 ± 0.13)x ‒ (0.47 ± 0.39)
(c)
2 3 4
‒1.0
‒0.5
0.0
0.5
1.0
1.5
2.0
2.5
Log[pro-BNP (pg/mL)]
O
SI
 (t
ot
al
 p
er
ox
id
e/
TA
C)
2 = 0.4
= 0.03
(1.5 ± 0.59)x ‒ (4.49 ± 2.1)
R
p
(d)
2 3 4
‒2
‒1
0
1
2
Log[pro-BNP (pg/mL)]
Lo
g[
H
N
E 
ar
ea
 (%
)]
2 = 0.394
= 0.0001
R
(0.68 ± 0.15)x ‒ (1.88 ± 0.44)
p
(e)
2 3 4
‒2
‒1
0
1
2
Log[pro-BNP (pg/mL)]
Lo
g[
H
N
E 
ar
ea
 (%
)]
2 = 0.1093
= 0.195
R
p
(f)
2 3 4
‒2.0
‒1.5
‒1.0
‒0.5
0.0
0.5
1.0
1.5
Log[pro-BNP (pg/mL)]
Lo
g[
N
T 
ar
ea
 (%
)]
= 0.005
2 = 0.22
(0.496 ± 0.164)x ‒ (0.997 ± 0.474)
R
p
(g)
2 3 4
‒2.0
‒1.5
‒1.0
‒0.5
0.0
0.5
1.0
1.5
Log[pro-BNP (pg/mL)]
Lo
g[
N
T 
ar
ea
 (%
)]
R
p = 0.829
2 = 0.003
(h)
Figure 3: Continued.
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Figure 3: Linear regression analysis of the relationship between oxidative-nitrative stress, PARP activity, or AIF translocation with pro-BNP
levels. (a) Linear regression of pro-BNP levels and plasma total peroxide in all subjects. (b) Linear regression of pro-BNP levels and plasma
total peroxide in CHF patients. (c) Linear regression of pro-BNP and oxidative stress index in all subjects. (d) Linear regression of pro-BNP
and oxidative stress index in CHF patients. (e) Linear regression of pro-BNP and leukocyte lipid peroxidation (4-hydroxynonenal (HNE)) in
all subjects. (f) Linear regression of pro-BNP and leukocyte lipid peroxidation (HNE) in CHF patients. (g) Linear regression of pro-BNP and
leukocyte tyrosine nitration in all subjects. (h) Linear regression of pro-BNP and leukocyte tyrosine nitration in the CHF patients. (i) Linear
regression of pro-BNP and leukocyte PARyalation in all patients. (j) Linear regression of pro-BNP and leukocyte PARyalation in the CHF
patients. (k) Linear regression of pro-BNP and leukocyte AIF translocation in all subjects. (l) Linear regression of pro-BNP and leukocyte
AIF translocation in the CHF patients. Increased pro-BNP levels are accompanied with increased oxidative stress (PRX, OSI) and PARP
activation of circulating mononuclear leukocytes either in the whole study cohort or in the CHF group alone. Lipid peroxidation, tyrosine
nitration, and AIF translocation in circulating mononuclear leukocytes however show correlation with the pro-BNP levels only in
the total study cohort. Continuous line represents the regression line, while dashed lines show the 95% confidence bends of the best-fit line.
R2: coefficient of determination; p: level of significance.
Table 3: Multivariate regression of the possible determinants of oxidative stress in chronic heart failure.
Total peroxide (μmol/l)
r2 = 0 977, pA < 0 002, N = 12
OSI
r2 = 0 978, pA < 0 001, N = 12
B SD of B pB B SD of B pB
Constant −1611.2 713.8 0.087 −2.629 0.927 0.047
Log[pro-BNP (pg/mL)] 991.7 154.5 0.003 1.402 0.201 0.002
IHD 362.4 127.5 0.047 0.421 0.166 0.064
LVEDD 26.3 25.7 0.362 0.059 0.033 0.151
LVESD −55.2 30.2 0.141 −0.101 0.039 0.062
Dependent variable was plasma total peroxide level (μmol/L), while independent variables were plasma pro-BNP, the occurrence of ischemic heart disease
(IHD), LVEDD, and LVESD. r2: coefficient of determination of the model; pA: significance level of the model; B: beta coefficient; pB: significance level of the
effect of each independent variable. OSI: oxidative stress index; pro-BNP: N-terminal probrain-type natriuretic peptide; IHD: ischemic heart disease;
LVEDD: left ventricular end diastolic diameter; LVESD: left ventricular end systolic diameter.
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findings showing that increased glucose concentrations or
glucose fluctuations induce the production of nitrogen-
derived free radicals and oxidants, involving peroxynitrite,
which in turn plays an important role in the pathogenesis
of type 1 and type 2 diabetes mellitus and in their complica-
tions including cardiovascular morbidities [20].
Experimental studies provided increasing number of evi-
dence of increased oxidative-nitrative stress-induced PARP
activation in the development of cardiac dysfunction. Central
role of PARP was observed in the pathogenesis of cardiac
and endothelial dysfunction in animal models of strepto-
zotocin induced and genetic diabetes mellitus [21]. The
animal model of heart failure with chronic aortic partial
occlusion was also found to be in association with PARP
activation [22]. The elevated activity of the enzyme was
also observed in doxorubicin-induced heart failure [23] and
endotoxin-induced cardiac depression (E. coli lipopolysac-
charide (LPS)) [24]. Despite of the high number of experi-
mental publications, fewer human or clinical studies were
published. Molnar et al. provided evidence of oxidative stress
and PARP activation in 8 human failing heart tissue samples
derived from organs that were explanted during heart trans-
plantation. But neither nitrotyrosine staining nor significant
translocation of apoptosis-inducing factor was presented
[25]. In sepsis-induced human heart failure, significant
PARP activation was detected by histological analysis of
heart sections and the level of activation correlated to both
troponin I and left ventricular systolic stroke work [26]. Poly
(ADP-ribosyl)ation in end-stage heart failure after left ven-
tricular assist device implantation was detected in human
myocardial biopsies [27]. One of the difficulties of establish-
ing human studies examining the role of any parameter in
the development of chronic heart failure is the limited
availability of freshly isolated human heart tissue samples.
According to our previous results, activation of PARP in
circulating leukocytes can be measured in PCI-treated
STEMI patients [14]. Moreover, Li et al. found that in human
septic shock PARP activity of circulating mononuclear cells
was strongly negatively correlated with ejection fraction
and showed to be an independent risk factor of myocardial
dysfunction [28]. Our present results confirmed the activa-
tion of PARP enzyme in human circulating leukocytes
derived from patients with chronic heart failure and the level
of activation correlated with severity of the disease. These
findings may suggest that investigating PARP activation in
human circulating leukocytes may serve as an eligible
method to describe systemic PARP activation with minimal
invasive intervention. It may provide an adequate research
or even clinical tool to examine the role of PARP activation
in cardiac failure.
According to recent findings, the activation of both
heart-hosted and circulating mononuclear cells can be
observed in chronic heart failure independently of the
etiology of CHF. The consequently evolving sustained patho-
logical chronic inflammation plays an important role in the
pathogenesis of the disease. The unbalanced T and B cell
activation described by various studies is shown to be
associated with cardiomyocyte death, tissue remodeling,
and fibrosis that may lead to the progression of the disease
[29]. The increased PARP activation in circulating mononu-
clear cells of CHF patients observed in our study may be
involved in the activation of these cells. Therefore, PARP
activation of these cells may not just follow the progression
of CHF, but they may also contribute to its pathogenesis.
Parthanatos is a new definition based on more detailed
results about PARP function in AIF translocation and
caspase-independent apoptotic cell death. In a mouse model,
heart failure induced by aortic constriction translocation of
AIF was attenuated by PARP inhibition [30]. Zhao et al.
demonstrated that in experimentally induced congestive
heart failure, PARP and AIF protein expression levels were
significantly higher in the CHF group than those in the
control group [31]. According to our previous results, activa-
tion of PARP was followed by the translocation of AIF in
PCI-treated STEMI patients [14]. In another human study,
increased AIF protein expression and a trend of AIF translo-
cation were observed in atrial tissues following cardioplegia
and cardiopulmonary bypass [32]. Furthermore, Molnar
et al. found no signs of AIF translocation neither in explanted
failing hearts nor in control healthy donor hearts during their
heart transplant studies [25]. In our present study, we were
able to show increased AIF translocation in circulating
mononuclear cells of CHF patients. Moreover, the level of
AIF translocation correlated with markers of cardiac func-
tion (EF, pro-BNP) and ventricular end diastolic diameter.
On the other hand, analyzing the CHF cohort revealed no
such correlations.
Our present results together with the previous findings
proved the presence of oxidative-nitrative stress-induced
PARP activation and its deleterious consequences in chronic
heart failure. The finding that these phenomena correlating
with the actual cardiac function can be even observed in
blood components may help to the better characterization
of the actual significance of PARP activation and parthanatos
in CHF. Additionally, further examinations may be required
to clarify the source of these systemic alterations and their
connection to cardiac function. The overall understanding
of these changes may also strengthen the concept of PARP
inhibitor treatment in CHF raised by several animal model
studies. The pharmaceutical inhibition and the genetic defi-
ciency of PARP were previously proven to be beneficial in
various types of heart failure. In doxorubicin-induced
heart failure of mice treatment with the PARP inhibitor
INO-1001 reduced mortality and cardiac depression [33].
The same inhibitor improved cardiac performance in aging
animals and also promoted acetylcholine-induced, nitric
oxide-dependent vascular relaxation [34]. Furthermore,
other PARP inhibitor PJ34 was shown to prevent Ca2+ over-
load and oxidative stress-induced myocardial contractile
disturbances in doxorubicin-treated rats [35]. In a rat model
of heart failure, PARP inhibition with INO-1001 improved
cardiac function after the permanent occlusion of the left
anterior descending coronary artery [33]. In a similar mouse
model, INO-1001 prevented the decline of cardiac function
and attenuated hypertrophy and tissue remodeling [30].
Several contributors of cardiac hypertrophy have been
previously identified; among others is angiotensin II, which
is recognized as one of the most potent stimulators of cardiac
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hypertrophy and remodeling. PARP-deficient mice were
shown to be protected from angiotensin II-induced cardiac
hypertrophy, and it was suggested that PARP contributes to
the angiotensin II-induced signaling pathways leading to
cardiac hypertrophy and failure [36]. In a spontanenously
hypertensive rat model, the chronic inhibition of PARP with
L-2286 prevented remodeling, preserved systolic function,
and delayed transition of hypertensive cardiopathy to heart
failure [37]. In a rat model of chronic heart failure induced
by isoproterenol-provoked myocardial infarction, the effect
of L-2286 was also investigated. The PARP inhibitor signifi-
cantly reduced the progression of heart failure by reducing
cardiac hypertrophy and interstitial fibrosis [38]. The anti-
remodeling effect of L-2286 was compared to the efficacy
of a widely used angiotensin-converting enzyme (ACE)
inhibitor, enalapril, in the same experimental model. The
PARP inhibitor was found to decrease the postinfarction
myocardial remodeling even more effectively than the
enalapril treatment [39].
5. Conclusion
Our present study showed that components of parthanatos
can be observed in the blood components of patients with
chronic heart failure; oxidative-nitrative stress, PARP activa-
tion, and AIF translocation also correlate to reduced cardiac
function. Moreover, oxidative stress and PARP activation
may also indicate the progression of heart failure. The posi-
tive correlation between leukocyte PARP activation and
pro-BNP may assign the minimal invasive measurement of
this parameter to a possible diagnostic tool for heart failure
progression monitoring. It may also serve as a potential early
detection tool for incipient heart failure. Our data may also
legitimate the further investigation of PARP inhibition, as a
therapeutic target in chronic heart failure.
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